Page last updated: 2024-12-06

acitretin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acitretin is a synthetic retinoid, a derivative of vitamin A, used primarily for the treatment of severe, recalcitrant psoriasis. It is synthesized through a multi-step process starting from retinoic acid. Acitretin exerts its therapeutic effects by modulating the growth and differentiation of keratinocytes, the main cells in the epidermis. It reduces inflammation, scaling, and plaque formation associated with psoriasis. The compound is also used for treating other skin conditions such as severe acne and erythroderma. Acitretin is studied extensively due to its unique mechanism of action and its efficacy in treating severe dermatological conditions. Research focuses on its therapeutic potential, side effects, and the development of more effective and safer retinoid-based treatments.'

Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID41317
CHEMBL ID3186098
MeSH IDM0026177
PubMed CID5284513
CHEMBL ID1131
CHEBI ID50173
CHEBI ID50172
SCHEMBL ID3759
MeSH IDM0026177

Synonyms (138)

Synonym
9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
FT-0661406
FT-0630674
NCGC00163127-05
AB07538
HMS3370M03
9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-1-oic acid
IHUNBGSDBOWDMA-UHFFFAOYSA-N
NCGC00163127-04
CHEMBL3186098
AKOS030228521
HMS3654J19
9-cis-acitretin
isoacitretin;ro 13-7652
HMS3744I21
DTXSID10860677
BIDD:GT0617
AC-4702
2,4,6,8-nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-
54757-46-9
soriatane
neotigason
acitretin
ro-10-1670/000
ro-10-1670
etretin
(2e,4e,6e,8e)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid
CHEBI:50173 ,
(2e,4e,6e,8e)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
acitretinum
acitretina
soriatane (tn)
D02754
55079-83-9
acitretin (usp/inn)
2,4,6,8-nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-e)-
einecs 259-474-4
tmmp
all-trans-acitretin
hsdb 7187
acitretina [spanish]
ro 10-1670/000
2,4,6,8-nonatetraenoic acid, 3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-, (all-e)-
acitretinum [latin]
acitretine [french]
ro 10-1670
retinoid etretin
acitretine
ccris 5534
SPECTRUM5_002065
all-trans-3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid
(all-e)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
NCGC00163127-02
DB00459
NCGC00163127-01
MLS001076667
smr000499573
acitretin, >=98.0% (hplc)
bdbm50088429
9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
ro-101670000
CHEMBL1131
NCGC00163127-03
HMS3259J12
dtxsid6022553 ,
tox21_112012
dtxcid902553
cas-55079-83-9
(2e,4e,6e,8e)-9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid
A830475
BCP9000229
HMS2234L17
soriatane ck
acitretin [usan:usp:inn:ban]
u0279
lch760e9t7 ,
unii-lch760e9t7
BCPP000437
CHEBI:50172 ,
acitretin [orange book]
acitretin [who-dd]
acitretin [usan]
acitretin [hsdb]
acitretin [usp-rs]
acitretin [mi]
acitretin [usp impurity]
acitretin [usp monograph]
acitretin [mart.]
acitretin [vandf]
acitretin [inn]
acitretin [ep monograph]
S1368
AKOS015889991
BRD-K90699611-001-01-4
CCG-220668
CS-1855
HY-B0107
gtpl7598
SCHEMBL3759
KS-5246
AB00698376-08
2,4,6,8-nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2e,4e,6e,8e)-
all-trans-etretin
(2e,4e,6e,8e)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
acitretin, british pharmacopoeia (bp) reference standard
AB00698376_09
acitretin, european pharmacopoeia (ep) reference standard
sr-01000763200
SR-01000763200-3
acitretin, united states pharmacopeia (usp) reference standard
acitretin, pharmaceutical secondary standard; certified reference material
acitretin; (all-e)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
HMS3714E17
SW199134-2
Q341500
13-cis-acitretin-d3
mfcd00866632
acitretin,(s)
AS-12644
STL565770
C75579
acitretin 100 microg/ml in acetonitrile:acetone
EN300-117242
13-is acitretin
BA164136
acitretin- bio-x
CS-0368934
EN300-1273239
trimethylmethoxyphenyl-retinoic acid
acitretinum (latin)
acitretin (usan:usp:inn:ban)
acitretin (usp monograph)
acitretin (usp impurity)
acitretin (ep monograph)
d05bb02
acitretin (usp-rs)
acitretin (mart.)
Z2312273468

Research Excerpts

Toxicity

Pioglitazone has a potential beneficial antipsoriatic effect and may provide a convenient, efficacious, and relatively safe option to combine with acitretin. The majority of the adverse events were mild to moderate except for 1 possibly unrelated episode of acute myocardial infarction.

ExcerptReferenceRelevance
" Apart from the well-known side effects affecting the mucous membranes, one patient developed biopsy- proven toxic hepatitis."( Efficacy and skeletal side effects of two years' acitretin treatment.
Austad, J; Kolbenstvedt, A; Mørk, NJ, 1992
)
0.28
" The main adverse effect in these two experiments was a reduced survival of the F1-generation."( Teratogenesis and reproductive safety evaluation of the retinoid etretin (Ro 10-1670).
Hummler, H; Kistler, A, 1985
)
0.27
"Topical 5% imiquimod cream seems to be safe on skin areas up to 60 cm2 in renal transplant recipients."( Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial.
Atkins, CL; Brown, VL; Cerio, R; Ghali, L; Harwood, CA; Proby, CM, 2005
)
0.33
" Adverse events were uncommon and none required the permanent discontinuation of treatment."( Puerto Rico psoriasis study group: efficacy and safety of etanercept.
Berlingeri-Ramos, AC; González-Chavez, JR; Sánchez Casiano, MA,
)
0.13
"To present a method for optimizing tolerance of systemic retinoids for chemoprevention and for monitoring and managing adverse events."( Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects.
Lebwohl, M; Otley, CC; Stasko, T; Tope, WD, 2006
)
0.33
"After reviewing the data on the use of systemic retinoids for chemoprevention, we developed a simplified approach for administering oral retinoids for chemoprevention of nonmelanoma skin cancer as well as basic guidelines for the prevention and management of adverse effects and appropriate laboratory monitoring."( Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects.
Lebwohl, M; Otley, CC; Stasko, T; Tope, WD, 2006
)
0.33
"Chemoprevention with systemic retinoids in patients with a history of numerous tumors or high-risk skin cancer can be optimized with graduated dose escalation and preventive strategies for the most common adverse effects."( Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects.
Lebwohl, M; Otley, CC; Stasko, T; Tope, WD, 2006
)
0.33
" Here we revisit the original phase 3 trials for acitretin to evaluate the evidence for low-dose therapy producing fewer adverse effects than the 50 mg/d dosage."( Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis.
Feldman, SR; Klinger, S; Murad, EJ; Pearce, DJ; Rowell, R; Ziel, KK, 2006
)
0.33
"The frequency of anomalies found after laboratory testing and clinical adverse events were the outcomes of interest."( Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis.
Feldman, SR; Klinger, S; Murad, EJ; Pearce, DJ; Rowell, R; Ziel, KK, 2006
)
0.33
"Common adverse effects (dry skin, alopecia, rhinitis, etc) were 2 to 3 times more frequent in subjects receiving 50-mg/d acitretin than in those receiving 25 mg/d."( Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis.
Feldman, SR; Klinger, S; Murad, EJ; Pearce, DJ; Rowell, R; Ziel, KK, 2006
)
0.33
"We have shown low-dose therapy (25 mg/d) to be an effective strategy for substantially reducing acitretin-associated adverse effects."( Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis.
Feldman, SR; Klinger, S; Murad, EJ; Pearce, DJ; Rowell, R; Ziel, KK, 2006
)
0.33
"5-month-old infant with IPP is presented, who was successfully treated with systemic retinoid therapy, which appears to be a safe and effective option for this challenging pustular eruption of childhood."( Acitretin is a safe treatment option for infantile pustular psoriasis.
Ergin, S; Ersoy-Evans, S; Ozkaya, O; Sahin, S, 2008
)
0.35
" The majority of the adverse events were mild to moderate except for 1 possibly unrelated episode of acute myocardial infarction in a 49-year-old woman in the acitretin plus placebo group."( Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial.
Dogra, S; Kaur, I; Malhotra, S; Mittal, R; Pandhi, P, 2009
)
0.35
"Pioglitazone has a potential beneficial antipsoriatic effect and may provide a convenient, efficacious, and relatively safe option to combine with acitretin, although further studies are needed."( Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial.
Dogra, S; Kaur, I; Malhotra, S; Mittal, R; Pandhi, P, 2009
)
0.35
"Although neuromuscular adverse effects represent significant clinical manifestations of hypervitaminosis A syndrome, surprisingly little attention has been paid to the potential neuromuscular toxicity of vitamin A derivatives (retinoids)."( Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians.
Chroni, E; Monastirli, A; Tsambaos, D, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The majority of adverse events were mucocutaneous, mild-to-moderate severity and dose dependent."( Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study.
Dogra, S; Jain, A; Kanwar, AJ, 2013
)
0.39
"Methotrexate is relatively inexpensive, safe and efficacious drug for the treatment of psoriasis patients with significant palmoplantar involvement."( Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study.
Handa, S; Janagond, AB; Kanwar, AJ, 2013
)
0.39
"Acitretin is a synthetic retinoid used for severe extensive psoriasis and it has been shown to be an effective and a safe therapeutic drug for other diseases including cancer when used in combination with other agents."( Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity.
Custódio, JB; Ribeiro, MP; Rocha-Pereira, P; Santos, MS; Santos-Silva, A; Silva, FS, 2013
)
0.39
" We registered demographic data, diagnoses, comorbidities, treatments and adverse events (AE)."( Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Alsina-Gibert, M; Belinchón, I; Carazo, C; Carrascosa, JM; Carretero, G; Dauden, E; De la Cueva-Dobao, P; Ferrán, M; Ferrandiz, C; García-Doval, I; Gómez-García, FJ; Herrera-Ceballos, E; Jiménez-Puya, R; López-Estebaranz, JL; Rivera, R; Sánchez-Carazo, JL; Torrado, R; Vanaclocha Sebastián, F, 2015
)
0.42
" The development of cutaneous neoplasms, including squamous cell carcinomas (SCCs), keratoacanthomas (KAs), and hyperkeratotic papules is one of the most common adverse effects of this therapy."( Vemurafenib-related cutaneous side effects ameliorated by acitretin.
Chon, SY; Geddes, ER; Sambrano, BL, 2014
)
0.4
" Patients were treated at an initial dose of 10 mg/day acitretin, which was then gradually increased until the best therapeutic effect with the fewest adverse effects was reached (< 50 mg/day) and later decreased and maintained at the lowest effective dosage."( Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety.
Bertoldi, AM; Borghi, A; Caroppo, F; Corazza, M; Virgili, A, 2015
)
0.42
"There was no significant difference in treatment efficacy between the TwHF and acitretin groups within 8 weeks, but there were fewer treatment-related adverse events in the TwHF group."( Efficacy and safety of Tripterygium wilfordii hook F versus acitretin in moderate to severe psoriasis vulgaris: a randomized clinical trial.
He, CX; He, YB; Jin, HZ; Li, F; Liu, TJ; Qiao, J; Shu, D; Wu, C; Yu, XL; Zhang, Y, 2015
)
0.42
" For both biologics and conventional systemics, there was no statistically significant intergroup difference in the rate of adverse events ( P=0."( Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Au, SC; Garber, C; Gottlieb, A; Plotnikova, N; Sorensen, EP, 2015
)
0.42
"This study provides preliminary evidence to suggest that biologic and conventional systemic therapies are similarly safe and effective in the elderly and non-elderly cohorts."( Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Au, SC; Garber, C; Gottlieb, A; Plotnikova, N; Sorensen, EP, 2015
)
0.42
" Mucocutaneous adverse effects occurred in all patients, but did not affect therapy maintenance."( Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective Analysis.
Belloni Fortina, A; Bonamonte, D; Cambiaghi, S; Corazza, M; Di Lernia, V; Di Nuzzo, S; Gisondi, P; Guarneri, C; Lasagni, C; Neri, I; Panzone, M, 2016
)
0.43
" The incidence of adverse events was similar across all arms."( A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients
Choe, YB; Choi, JH; Kim, KJ; Kim, NI; Kim, TY; Lee, JH; Park, CJ; Song, HJ; Yoo, HJ; Youn, JI, 2016
)
0.43
" Efficacy, adverse events, reasons for discontinuation, 1, 2- and 3-year drug survival rates, and determinants of drug survival were analyzed."( Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study.
Alpsoy, E; Bulbul-Baskan, E; Ergun, T; Onsun, N; Salman, A; Saricam, MH; Sarioz, A; Seckin Gencosmanoglu, D, 2017
)
0.46
" TGP combined with acitretin is a safe and effective treatment approach for moderate-to-severe plaque psoriasis."( Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.
Fan, X; Li, Z; Liu, X; Wang, G; Yu, C, 2017
)
0.46
" Additionally, a skin in vitro evaluation assay provided the first known evidence of side-effect reduction with pro-drug use."( Synthesis and in vitro cytotoxicity evaluation of star-shaped polymethacrylic conjugates with methotrexate or acitretin as potential antipsoriatic prodrugs.
Gabriel, A; Gogler-Piglowska, A; Kupczak, M; Michalski, M; Mielanczyk, A; Mielanczyk, Ł; Mrowiec, K; Neugebauer, D; Scieglinska, D; Skonieczna, M, 2020
)
0.56
" However, an unintended but frequent consequence of ICI therapy is the development of cutaneous immune-related adverse events (irAEs), such as lichenoid dermatitis irAEs (LD-irAEs)."( Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Aung, PP; Curry, JL; Duke, TC; Glitza Oliva, IC; Ledesma, DA; Marques-Piubelli, ML; Nagarajan, P; Nelson, KC; Prieto, VG; Tetzlaff, MT; Torres-Cabala, CA; Wistuba, II, 2020
)
0.56
"Acitretin, apremilast, and methotrexate are safe and effective modalities for ICI-mediated psoriasis."( Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Annunziata, MC; Apalla, Z; Carrera, C; Fabbrocini, G; Fattore, D; Giacchero, D; Lallas, A; Lallas, K; Lazaridou, E; Nikolaou, V; Ortiz-Brugués, A; Patri, A; Peris, K; Riganti, J; Rigopoulos, D; Romano, MC; Rossi, E; Sibaud, V; Sollena, P; Stratigos, AJ; Voudouri, D, 2021
)
0.62
" Adverse events were comparatively more in ACT group as compared to MTX and CSA groups."( Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study.
Chavan, D; Jamale, V; Kale, M; Nikam, B; Shah, S, 2021
)
0.62
" Alternatively, we used a combination of secukinumab with low-dose acitretin, which resulted in a complete or almost complete skin clearance in all patients, with no adverse events or increased toxicity."( Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: A case series of high efficacy and safety profile.
Babuna Kobaner, G; Bölük, KN; Polat Ekinci, A, 2021
)
0.62
" Despite its frequent use, research on drug survival and adverse effects is limited."( Drug survival and safety profile of acitretin monotherapy in patients with psoriasis: A multicenter retrospective study.
Aslan Kayıran, M; Aytekin, S; Kara Polat, A; Karadag, AS; Kıvanc Altunay, I; Koku Aksu, AE; Oguz Topal, I; Ozkok Akbulut, T; Ozkur, E; Topaloglu Demir, F, 2021
)
0.62
"Breakthrough targeted therapies have produced significant improvements in survival for cancer patients, but have a propensity to cause cutaneous immune-related adverse events (irAEs)."( Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.
Aung, PP; Cho, WC; Curry, JL; Gill, P; Heberton, M; Murphy, MB; Nagarajan, P; Nikolaou, V; Om, A; Patel, AB; Ruiz-Bañobre, J; Seervai, RNH; Torres-Cabala, CA; Yamamoto, T, 2022
)
0.72
" No adverse effects were reported in the patients in the study."( Anti-IL23for nail psoriasis in real life: Results of efficacy and safety during a 52-week period.
Capalbo, E; Cartocci, A; Cinotti, E; Cortonesi, G; Orsini, C; Rubegni, P; Trovato, E, 2022
)
0.72
"Current evidence showed that CHM bath and fumigation appeared to be efficient and safe for PV treatment."( Efficacy and safety of external application of Chinese herbal medicine for psoriasis vulgaris: a systematic review of randomized controlled trials.
Haiyan, H; Lingling, LI; Xiaoran, Z; Xun, LI; Yi, L; Zi, W, 2022
)
0.72
" Most patients did not suffer any adverse events, and no severe side effects were observed."( Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study.
Arias-Santiago, S; Díaz-Calvillo, P; Molina-Leyva, A; Rodríguez-Pozo, JÁ; Sánchez-Díaz, M, 2023
)
0.91
" Herein, we discuss adverse events, contraindications, drug-drug interactions, screening/monitoring guidelines, as well as utilization for special populations, including pregnant, older, and pediatric patients."( Safety of current systemic therapies for nail psoriasis.
Hwang, JK; Lipner, SR,
)
0.13
"The advent of targeted therapies, including biologic treatments and small molecule inhibitors, has revolutionized outcomes for nail psoriasis patients, but warrant review and monitoring for potential adverse events."( Safety of current systemic therapies for nail psoriasis.
Hwang, JK; Lipner, SR,
)
0.13

Pharmacokinetics

The purpose of this study was to validate an HPLC method for the determination of acitretin and etretinate. The pharmacokinetic characteristics of ac itretin in the Korean population were investigated. The mean +/- SD pharmacokinetics of acItretIn in Koreans were as follows: Cmax 148.

ExcerptReferenceRelevance
" The purpose of the present study was to investigate the pharmacokinetic profile of etretinate and acitretin in a genetically obese rodent model, the Zucker rat."( Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat.
Blouin, RA; McNamara, PJ, 1990
)
0.28
" The large Vdss (214 +/- 228 liters/kg) of ET and terminal half-life of greater than 300 hr indicated the wide distribution and prolonged storage of ET in the tissues."( The pharmacokinetics of etretinate and its metabolites in the dog.
Massarella, JW; Thongnopnua, P; Zimmerman, CL,
)
0.13
" Hitherto, the use of the carboxylic acid ester analogue, etretinate, has been hampered by an extremely long elimination half-life of up to 120 days for this drug."( Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients.
Jakobsen, P; Kragballe, K; Larsen, CG; Larsen, FG; Nielsen-Kudsk, F, 1988
)
0.27
" These differences between the results obtained in vivo and in vitro could be resolved by pharmacokinetic investigations using HPLC methods."( Transplacental pharmacokinetics of teratogenic doses of etretinate and other aromatic retinoids in mice.
Kochhar, DM; Kraft, JC; Löfberg, B; Nau, H; Reiners, J, 1988
)
0.27
" The purpose of this study was to validate an HPLC method for the determination of acitretin and etretinate and to investigate the pharmacokinetic characteristics of acitretin in healthy Korean subjects."( A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects.
Chun, MR; Huh, WS; Kim, DW; Kim, HG; Kim, HK; Kim, JW; Kim, MH; Kim, YG; Lee, JH; Lee, SY; Park, HD; Youn, JI, 2009
)
0.35
" The mean +/- SD pharmacokinetics of acitretin in Koreans were as follows: Cmax 148."( A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects.
Chun, MR; Huh, WS; Kim, DW; Kim, HG; Kim, HK; Kim, JW; Kim, MH; Kim, YG; Lee, JH; Lee, SY; Park, HD; Youn, JI, 2009
)
0.35
"A simple HPLC method for the simultaneous determination of acitretin and etretinate was validated, and the pharmacokinetic characteristics of acitretin in the Korean population were investigated."( A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects.
Chun, MR; Huh, WS; Kim, DW; Kim, HG; Kim, HK; Kim, JW; Kim, MH; Kim, YG; Lee, JH; Lee, SY; Park, HD; Youn, JI, 2009
)
0.35

Compound-Compound Interactions

Longest survival on a biologic combined with methotrexate, acitretin or cyclosporin was 103, 78 and 34 months, respectively. Chinese herbal medicine combined with ac itretin capsule in treating psoriasis of blood-heat syndrome (P-BH)

ExcerptReferenceRelevance
"In a randomized, double-blind comparative study 60 patients with severe, widespread psoriasis were treated either with photochemotherapy (PUVA) alone or in combination with acitretin."( Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study.
Fritsch, P; Geiger, JM; Guggenbichler, A; Hönigsmann, H; Tanew, A, 1991
)
0.28
" The present study shows that acitretin is as effective as etretinate in the combination with bath PUVA."( A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis.
Geiger, JM; Lauharanta, J, 1989
)
0.28
" The retinoids given in combination with MMC produced additive effects."( [Inhibitory effects of aromatic retinoic acid analog, administered alone or in combination with mitomycin C, on the in vitro growth of rat bladder carcinoma cells].
Fujita, J; Yoshida, O, 1984
)
0.27
"Interferon-alpha combined with retinoid or PUVA is used for the treatment of cutaneous T-cell lymphoma."( Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA.
Burg, G; Dummer, R; Joller-Jemelka, HI; Prümmer, O; Rajan, GP; Seifert, B, 1996
)
0.29
"The purpose of this study was to assess how oral retinoids are used in combination with other drugs to treat psoriasis."( The frequent use of oral retinoids in combination with other treatments for psoriasis: a retrospective analysis.
Balkrishnan, R; Camacho, F; Feldman, SR; Fleischer, AB; Hu, J; Lang, W; Pearce, DJ,
)
0.13
"Use of acitretin in combination with many other psoriasis treatments is a common practice."( The frequent use of oral retinoids in combination with other treatments for psoriasis: a retrospective analysis.
Balkrishnan, R; Camacho, F; Feldman, SR; Fleischer, AB; Hu, J; Lang, W; Pearce, DJ,
)
0.13
"The concomitant use of systemic anti-psoriatic medication in combination with alefacept has a noteworthy impact on efficacy results."( The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
De Jong, EM; Langewouters, AM; Van De Kerkhof, PC; Van Erp, PE, 2006
)
0.33
" Based on the findings, the antitumor effects of a selected retinoid either alone or in combination with cisplatin were also investigated in a preclinical mouse melanoma model."( Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.
Chan, SY; Ho, PC; Liu, X, 2008
)
0.35
"Cell proliferation and invasion analyses of murine melanoma B16-F10 cells were assessed in the presence of different retinoids, either alone or in combination with cisplatin (CDDP) or 5-fluorouracil (5-FU)."( Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.
Chan, SY; Ho, PC; Liu, X, 2008
)
0.35
"To observe the clinical curative effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome (P-BH)."( Effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome type.
Bai, YP; Song, PH; Yang, DQ; You, LP; Zhang, LX, 2009
)
0.35
"The effect of Chinese herbal medicine combined with acitretin capsule was superior to Chinese herbal medicine alone in treating P-BH, but the adverse reaction of acitretin capsule could be alleviated by adjusting the herbs used."( Effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome type.
Bai, YP; Song, PH; Yang, DQ; You, LP; Zhang, LX, 2009
)
0.35
" We present the case in which erythroderma was most likely triggered by acitretin combined with ceftriaxone."( Psoriatic erythroderma coexisting with erythema multiforme-like lesions induced by retinoids or retinoids combined with an antibiotic: case report.
Chodorowska, G; Hercogova, J; Jazienicka, I; Krupski, W; Lotti, T; Mieczkowska, J; Mosiewicz, J; Osemlak, P; Pietrzak, A; Szepietowski, JC; Szubstarski, F; Terlecki, P; Wawrzycki, B; Zubilewicz, T,
)
0.13
"Acitretin is currently used alone or combined with PUVA (psoralen + UVA) or with narrow-band ultraviolet B (NBUVB), to treat moderate and severe psoriasis."( Cytotoxic and genotoxic effects of acitretin, alone or in combination with psoralen-ultraviolet A or narrow-band ultraviolet B-therapy in psoriatic patients.
Bronze-da-Rocha, E; Custódio, JB; Fernandes, JC; Figueiredo, A; Moreiras, A; Oliveira, H; Rocha-Pereira, P; Santos-Silva, A; Silva, FS, 2013
)
0.39
" This review evaluates the effects of oral CHM in combination with pharmacotherapy for psoriasis vulgaris."( Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review.
Lu, C; May, B; Parker, S; Xue, CC; Yu, JJ; Zhang, AL; Zhang, CS, 2014
)
0.4
" Immunosuppressants that inhibit mTOR, such as sirolimus, may be used in combination with a systemic retinoid for chemoprophylaxis of cutaneous malignancies."( Serum Sirolimus Level Elevation Induced by Acitretin: Report of a Novel Drug-Drug Interaction.
Hibler, BP; Johnson-Jahangir, H; Rossi, AM, 2015
)
0.42
" To investigate the efficacy and safety of total glucosides of paeony (TGP) combined with acitretin in the treatment of moderate-to-severe plaque psoriasis."( Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.
Fan, X; Li, Z; Liu, X; Wang, G; Yu, C, 2017
)
0.46
"We collected data on frequency of use, demographics, treatment characteristics and drug survival of biologics combined with conventional systemic agents or phototherapy in five PSONET registries."( Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Addis, A; Adenubiova, E; Busard, CI; Cazzaniga, S; Cohen, AD; Feldhamer, I; Gkalpakiotis, S; Hutten, BA; Kojanova, M; Lichem, R; Naldi, L; Quehenberger, F; Spuls, PI; Stern, RS; Wolf, P, 2018
)
0.48
" Longest survival on a biologic combined with methotrexate, acitretin or cyclosporin was 103, 78 and 34 months, respectively."( Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Addis, A; Adenubiova, E; Busard, CI; Cazzaniga, S; Cohen, AD; Feldhamer, I; Gkalpakiotis, S; Hutten, BA; Kojanova, M; Lichem, R; Naldi, L; Quehenberger, F; Spuls, PI; Stern, RS; Wolf, P, 2018
)
0.48
" This study was designed to investigate the role and related mechanisms of matrine alone and in combination with acitretin in the treatment of psoriasis in vitro and in vivo."( Role and mechanism of matrine alone and combined with acitretin for HaCaT cells and psoriasis-like murine models.
Jiang, WW; Wang, XY; Wang, YM; Zhang, CL; Zhang, Q; Zhu, SM, 2019
)
0.51
" Through network meta-analysis, the current study evaluated the efficacy and safety of systemic retinoids alone or combined with other remedies in the treatment of warts."( Efficacy of retinoids alone or in combination with other remedies in the management of warts: A systematic review and network meta-analysis.
Abdel Daim, MM; Agha, NY; Anis, R; Awad, M; El-Shirbiny, H; Fathi, M; Ibrahim, AM; S A Shehata, M; Salman, S; Sarsik, S, 2021
)
0.62
" This review evaluates the clinical therapeutic effects of Xiaoyin granule, a Chinese herbal medicine, combined with acitretin capsule in the treatment of psoriasis vulgaris."( A Meta-analysis of Xiaoyin Granules Combined with Acitretin Capsule in the Treatment of Psoriasis Vulgaris.
Geng, A; Jia, B; Pei, T; Zhao, X, 2022
)
0.72
" We investigated the effects of aminolevulinic acid-based photodynamic therapy (ALA-PDT) combined with oral acitretin during therapy of refractory CA in the anal canal."( ALA-PDT combined with oral acitretin in the treatment of refractory condyloma acuminatum in anal canal.
Chen, N; Cheng, Q; Lei, X; Li, J; Tang, H; Wu, J; Zeng, Q; Zhang, L, 2022
)
0.72
" ALA-PDT group with 51 patients was given ALA-PDT treatment, and ALA-PDT plus acitretin group with 50 patients was given ALA-PDT treatment combined with oral acitretin."( ALA-PDT combined with oral acitretin in the treatment of refractory condyloma acuminatum in anal canal.
Chen, N; Cheng, Q; Lei, X; Li, J; Tang, H; Wu, J; Zeng, Q; Zhang, L, 2022
)
0.72
"ALA-PDT combined with oral acitretin is effective and safe in the treatment of refractory CA in anal canal, and with further study may become an option for these patients."( ALA-PDT combined with oral acitretin in the treatment of refractory condyloma acuminatum in anal canal.
Chen, N; Cheng, Q; Lei, X; Li, J; Tang, H; Wu, J; Zeng, Q; Zhang, L, 2022
)
0.72

Bioavailability

The mean absolute bioavailability of acitretin is 59% with high interpatient variability consistent with that of etretinate. Topical administration of ac itretin may lessen the risk of systemic toxicity.

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The mean absolute bioavailability of acitretin is 59% with high interpatient variability consistent with that of etretinate."( Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin).
Brindley, CJ, 1989
)
0.28
" Administration of ET, ETA, and c-ETA by several routes of administration allowed the use of a physiologically based model to assess the relative contributions of absorption and presystemic metabolism to the oral bioavailability of these compounds."( The pharmacokinetics of etretinate and its metabolites in the dog.
Massarella, JW; Thongnopnua, P; Zimmerman, CL,
)
0.13
" The presence of food increases the apparent bioavailability of acitretin."( Food increases the bioavailability of acitretin.
Brindley, CJ; Jensen, BK; Jewell, RC; McNamara, PJ, 1988
)
0.27
"Since etretinate, an aromatic retinoid useful in the treatment of psoriasis and other skin disorders is lipid-soluble, it may be poorly absorbed in the absence of a fat load."( Etretinate: effect of milk intake on absorption.
DiGiovanna, JJ; Gantt, G; Gross, EG; McClean, SW; Peck, GL; Ruddel, ME, 1984
)
0.27
" We also found that the RMBCD-based formulation of acitretin improved its bioavailability and decreased the variations in various pharmacokinetic parameters."( Biopharmaceutics of beta-cyclodextrin derivative-based formulations of acitretin in Sprague-Dawley rats.
Chan, SY; Ho, PC; Lin, HS; Liu, X, 2004
)
0.32
" Topical administration of acitretin may lessen the risk of systemic toxicity while increasing local bioavailability in the skin."( Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse.
Chern, WH; Hofland, HE; Houlden, RJ; Hsia, E; Johnston, MJ, 2008
)
0.35
" The future of retinoid cancer chemoprevention depends on the development and research of novel retinoids with improved bioavailability and minimized toxicity."( Systemic retinoids in chemoprevention of non-melanoma skin cancer.
Lens, M; Medenica, L, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The purpose of this double-blind study was to compare the therapeutic effects of a low initial dosage of acitretin, increased at 2-week intervals. The in vitro incubation was performed using rat and human liver 12,000 g supernatant, and the in vivo experiment was conducted in rats after oral dosing of ac itretin.

ExcerptRelevanceReference
" When used alone at a maintenance dosage of 30 to 50mg daily, acitretin is effective in the treatment of psoriasis, causing a reduction in the severity of scaling, erythema and induration."( Acitretin. A review of its pharmacology and therapeutic use.
Brogden, RN; Pilkington, T, 1992
)
0.28
" Secondary maxima were induced by administering ethanol alone at 5 and 8 h after dosing with acitretin."( A potentially new metabolic pathway: ethyl esterification of acitretin.
Chou, RC; Huselton, CA; Wiegand, UW; Wyss, R, 1992
)
0.28
" after single and multiple dosing (50 mg orally for 13 days) in plasma, blister fluid and epidermal samples from four healthy male volunteers."( The distribution of cis- and trans-acitretin in human epidermis.
De Bersaques, J; De Leenheer, A; Kint, A; Lambert, W; Meyer, E, 1992
)
0.28
"The purpose of this open, noncomparative study with acitretin (Ro 10-1670) was to evaluate the clinical response of patients with various nonpsoriatic disorders of keratinization and to establish for these patients the optimal dosage for both efficacy and tolerance."( Acitretin in the treatment of severe disorders of keratinization. Results of an open study.
Blanchet-Bardon, C; Geiger, JM; Nazzaro, V; Puissant, A; Rognin, C, 1991
)
0.28
" The in vitro incubation was performed using rat and human liver 12,000 g supernatant, and the in vivo experiment was conducted in rats after oral dosing of acitretin."( A newly discovered xenobiotic metabolic pathway: ethyl ester formation.
Chou, RC; Huselton, CA; Wiegand, UW; Wyss, R, 1991
)
0.28
"Retinoid transfer into breast milk was studied in a psoriatric woman receiving oral acitretin at a dosage of 40 mg once daily."( Acitretin excretion into human breast milk.
Pihl-Lundin, I; Rollman, O, 1990
)
0.28
" and 161 ng/ml for A 4h after dosing (tmax)."( [Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use].
Bitterling, T; Gollnick, H; Orfanos, CE; Rinck, G, 1990
)
0.28
" Pairs of obese and lean Zucker rats were dosed intravenously (0."( Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat.
Blouin, RA; McNamara, PJ, 1990
)
0.28
" Further reduction of the dosage resulted in a relapse within a few days."( Acitretin in the treatment of erythrokeratodermia variabilis.
Happle, R; Steijlen, PM; van de Kerkhof, PC; van Dooren-Greebe, RJ, 1990
)
0.28
" However, a dosage of 35 mg/day resulted in a significant inhibition of PMN accumulation, dosages of 45 and 55 mg/day causing an even more pronounced inhibition of this process."( Intra-epidermal accumulation of polymorphonuclear leukocytes in persistent palmoplantar pustulosis during treatment with acitretin.
Chang, A; Geiger, JM; Happle, R; van de Kerkhof, PC; van Dooren-Greebe, R, 1988
)
0.27
" Afterwards the dosage regimens were kept unchanged until day 40 when 60 mg oral vitamin K1 were administered."( Lack of effect of acitretin on the hypothrombinemic action of phenprocoumon in healthy volunteers.
Hartmann, D; Mosberg, H; Weber, W, 1989
)
0.28
"The purpose of this double-blind study was to compare the therapeutic effects of a low initial dosage of acitretin, increased at 2-week intervals (group 1: 10, 30, 50 mg/day) with a high initial dosage decreased at similar intervals (group 3: 50, 30, 10 mg/day) and with a constant dosage (group 2: 30 mg/day) in 66 patients (47 men and 19 women) with severe psoriasis."( Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis.
Berbis, P; Geiger, JM; Privat, Y; Rognin, C; Vaisse, C, 1989
)
0.28
" After the double-blind phase, the patients were allowed to continue for a total of 6 months of acitretin therapy at an average dosage of 50 mg/day."( Side-effect profile of acitretin therapy in psoriasis.
Ellis, CN; Goldfarb, MT; Gupta, AK; Voorhees, JJ, 1989
)
0.28
" After a further dosage reduction to 5 mg/day there were no obvious side effects and a long-term treatment was possible, resulting in an obvious reduction of the ichthyotic lesions and improved hair growth."( [Successful retinoid therapy of Netherton syndrome].
Hartschuh, W; Hausser, I; Petzoldt, D, 1989
)
0.28
" After a 4-week interval of either etretin (50 mg/day) or placebo (randomized), all patients received etretin during a second period of 20 weeks (the dosage was individually varied)."( Pustulosis palmo-plantaris. Clinical and histological changes during etretin (acitretin) therapy.
Altmeyer, P; el-Gammal, S; Holzmann, H; Schröder, K; Zaun, H, 1989
)
0.28
"The aim of the study was to investigate the concentrations of Ro 10-1670 (acitretin) and its isomeric metabolite Ro 13-7652 (cis-acitretin) after multiple oral dosing of acitretin."( Determination of acitretin and 13-cis-acitretin in skin.
Berbis, P; Brindley, C; Bun, H; Durand, A; Geiger, JM; Laugier, JP; Privat, Y, 1989
)
0.28
"In a patient affected with acrodermatitis continua Hallopeau, acitretin (Ro 10-1670) monotherapy resulted in a complete clearance of pustulation at a dosage of 45 mg per day."( Acitretin monotherapy in acrodermatitis continua Hallopeau.
Chang, A; Happle, R; van de Kerkhof, PC; van Dooren-Greebe, RJ, 1989
)
0.28
" Steady state trough concentrations of acitretin in nonpregnant animals following etretinate multiple dosing reached their peak levels (53 ng/ml) at day 7 and declined to 16 ng/ml at day 19."( Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. II. Single and multiple oral dosing studies.
Brouwer, KR; McNamara, PJ,
)
0.13
" Drug concentration and metabolism in plasma and skin samples appeared to be linked in that the trans-isomer concentration was always higher than the cis-isomer concentration during dosing and 3 h after the last dose."( Determination of acitretin in the skin, in the suction blister, and in plasma of human volunteers after multiple oral dosing.
Bun, H; Durand, A; Geiger, JM; Laugier, JP; Maibach, HI; Surber, C; Wilhelm, KP, 1994
)
0.29
" To test this hypothesis, male and female Sprague-Dawley rats were orally pretreated with acitretin for 18 days (10 mg/kg/day) and intravenously dosed with acitretin on day 20 (0."( Hepatic enzyme induction potential of acitretin in male and female Sprague-Dawley rats.
McNamara, PJ; Small, DS, 1994
)
0.29
" The aim of the present study was to provide further information on acitretin dosage regimens in the management of lamellar ichthyosis."( Acitretin in the treatment of lamellar ichthyosis.
Steijlen, PM; Van de Kerkhof, PC; Van Dooren-Greebe, RJ, 1994
)
0.29
" Based on this data we addressed the question whether the topical administration of acitretin can produce in humans a drug concentration in the skin which exceeds the drug concentration that is found in the skin after multiple oral acitretin dosing and is reported to be clinical effective."( [Distribution of acitretin in human skin].
Durand, A; Geiger, JM; Laugier, JP; Maibach, HI; Rufli, T; Surber, C, 1993
)
0.29
" No untoward effects of gemfibrozil on acitretin dose-response and clinical side-effects were noted."( Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study.
Lindholm, A; Olsson, AG; Vahlquist, A; Vahlquist, C, 1995
)
0.29
" Dose-response studies have established the effective dose range of acitretin as well as the dose-dependence of its side effects."( Acitretin: optimal dosing strategies.
Ling, MR, 1999
)
0.3
" Severe cutaneous forms of lichen planus were recently recognized as indications of acitretin treatment; 35 to 40 mg daily is the mean effective dosage in adults (0."( [Acitretine].
Berbis, P,
)
0.13
" Three controlled clinical trials have demonstrated that the addition of calcipotriene ointment to systemic antipsoriatic treatment with MTX, acitretin, and cyclosporine increases the therapeutic efficacy compared with systemic therapy alone and minimizes side effects by either reducing the dosage or duration of treatment."( Vitamin D and systemic therapy.
van de Kerkhof, P, 2002
)
0.31
" No optimal long-term dosing advice is available."( Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin.
de Jong, EM; de Sévaux, RG; Hoitsma, AJ; Smit, JV; van de Kerkhof, PC, 2003
)
0.32
" After single intravenous dosing (2."( Biopharmaceutics of beta-cyclodextrin derivative-based formulations of acitretin in Sprague-Dawley rats.
Chan, SY; Ho, PC; Lin, HS; Liu, X, 2004
)
0.32
" Mucocutaneous side effects of oral retinoids are common but with appropriate dosing are generally mild."( The frequent use of oral retinoids in combination with other treatments for psoriasis: a retrospective analysis.
Balkrishnan, R; Camacho, F; Feldman, SR; Fleischer, AB; Hu, J; Lang, W; Pearce, DJ,
)
0.13
" Dose adjustment was allowed during the open-label phase, during which high-dose treatment was defined as a mean dosage of 50 mg/d and low-dose treatment was defined as a mean dosage of 25 mg/d."( Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis.
Feldman, SR; Klinger, S; Murad, EJ; Pearce, DJ; Rowell, R; Ziel, KK, 2006
)
0.33
" Typical regimens for NB-UVB involve dosing 3 times per week for at least 3 months."( A review of phototherapy protocols for psoriasis treatment.
Bagel, J; Feldman, SR; Halvorson, CR; Lapolla, W; Yentzer, BA, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"Individualization of acitretin dosing is crucial to minimize side effects and should lead to improved adherence and efficacy."( Efficacy of low-dose acitretin in the treatment of psoriasis.
Dabade, TS; Feldman, SR; Haushalter, K; Murad, EJ; Pearce, DJ; Rowell, R, 2012
)
0.38
"Acitretin 35 mg/day was observed to be more efficacious compared to 25 mg/day and 50 mg/day dosing, whereas its safety profile is better than 50 mg/day dosing in the management of severe plaque type psoriasis in adult patients."( Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study.
Dogra, S; Jain, A; Kanwar, AJ, 2013
)
0.39
"Despite numerous studies of the literature concerning retinoids in chemoprevention of NMSC, precise details of the type of retinoid to use, dosage and the duration of this preventive treatment and how to manage side effects in the case of long-lasting treatment are still not uniform and comparable."( Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how.
Bettoli, V; Virgili, A; Zauli, S, 2013
)
0.39
"Acitretin should be considered as a chemopreventative agent for VK and cuSCC in patients taking BRAF inhibitors, before considering dosage reductions."( Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.
Anforth, R; Blumetti, TC; Clements, A; Fernandez-Peñas, P; Kefford, R; Long, GV, 2013
)
0.39
" Side effects are common but usually mild and can be managed by its proper dosing and monitoring."( Acitretin in psoriasis: an evolving scenario.
Dogra, S; Yadav, S, 2014
)
0.4
" Isotretinoin seems to provide the best chance at remission, but the number of reports is small, dosing schedules variable, and the long term follow up beyond a year is negligible; treatment failures have been reported."( Dissecting cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppura
Scheinfeld, N, 2014
)
0.4
"We treated a series of 4 patients with GPP with ustekinumab, which was applied on an outpatient basis according to the dosing regimen approved for psoriasis vulgaris."( Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa, A; Prinz, JC; Ruzicka, T, 2016
)
0.43
" Treatment regimens can include medications that are not available in pediatric dosage form."( Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis.
Choo, W,
)
0.13
" Most patients exhibited a marked response to acitretin, but patients who were prescribed a maintenance dosage (10-30 mg/d) had mild recurrence (0-2 times/year) during follow-up."( Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis.
Jin, H; Li, F; Shu, D; Wu, C; Zhu, T, 2018
)
0.48
" All patients were treated with an initial dosage of 10 mg acitretin daily."( Acitretin treatment in antimalarial-refractory/intolerant discoid lupus erythematosus: A prospective, open-label, uncontrolled study.
Chiewchanvit, S; Chuamanochan, M; Laosakul, K; Tovanabutra, N, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
keratolytic drugA drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
retinoidOxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
acitretinA retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.
retinoidOxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
alpha,beta-unsaturated monocarboxylic acidA monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Signaling Pathways1269117
Signaling by Nuclear Receptors15246
Signaling by Retinoic Acid2431

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency11.98770.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency23.91850.01238.964839.8107AID1645842
Interferon betaHomo sapiens (human)Potency23.91850.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency40.53340.007215.758889.3584AID624030
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency12.45180.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency12.01080.000221.22318,912.5098AID743035; AID743036; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.66930.000229.305416,493.5996AID743069; AID743075; AID743077; AID743078; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency3.11010.001019.414170.9645AID743094; AID743140
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.23710.001723.839378.1014AID743083
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency14.90730.000323.4451159.6830AID743065; AID743066; AID743067
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
eyes absent homolog 2 isoform aHomo sapiens (human)Potency21.33491.199814.641950.1187AID720540
DNA polymerase eta isoform 1Homo sapiens (human)Potency100.00000.100028.9256213.3130AID588591
gemininHomo sapiens (human)Potency17.40410.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.57250.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency3.16230.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency23.75300.251215.843239.8107AID504327
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency70.79466.309660.2008112.2020AID720709
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631; AID720552
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency10.00003.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)49.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)19.70000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)28.20000.11007.190310.0000AID1209455; AID1473738
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (228)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (75)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (51)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (125)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1130660Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas at 10 mg/kg, ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID548961Antioxidant activity of the compound assessed as reducing activity of DPPH at 0.1 mM after 60 mins2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1136167Activity against chemically-induced skin papillomas in Swiss albino mouse assessed as change in total papilloma diameter at 10 mg/kg/day, ip administered five times per week for 2 weeks measured on day 141977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID548957Inhibition of soybean lipoxygenase at 0.1 mM2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID548962Cytotoxicity against RAMEC assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1130653Toxicity in mouse assessed as hypervitaminosis dose compound treated ip daily monday through friday in first week and monday through thursday in second week measured after 1 day of last injection1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473887AUC in human at 25 to 50 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID548959Antioxidant activity against AAPH-induced lipid peroxidation assessed as inhibition of conjugated diene hydroperoxide production at 0.1 mM by UV spectrophotometry2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID548960Antioxidant activity of the compound assessed as reducing activity of DPPH at 0.1 mM after 20 mins2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1136169Reversal of keratinized lesions in vitamin A deficient hamster tracheal organ culture assessed as cultures with keratin and keratohyaline granules at 0.1 uM after 7 days (Rvb = 93%)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID1130661Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas at 5 mg/kg, ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1136172Reversal of keratinized lesions in vitamin A deficient hamster tracheal organ culture assessed as cultures with keratin and keratohyaline granules at 1 uM after 7 days (Rvb = 93%)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID442513Antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/Kg, ip administered simultaneously with carrageenan measured after 3.5 hrs relative to control2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Syntheses and evaluation of the antioxidant activity of acitretin analogs with amide bond(s) in the polyene spacer.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548963Antiinflammatory activity in Fisher rat assessed as inhibition of carrageenan-induced paw oedema at 0.01 mmol/kg, po measured after 3.5 hrs2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID1473889Ratio of drug concentration at steady state in human at 25 to 50 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1136171Reversal of keratinized lesions in vitamin A deficient hamster tracheal organ culture assessed as cultures with keratin and keratohyaline granules at 1 nM after 7 days (Rvb = 93%)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1130659Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas at 20 mg/kg, ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1473888Drug concentration at steady state in human at 25 to 50 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1473890Ratio of drug concentration at steady state in human at 25 to 50 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1130658Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas at 40 mg/kg, ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136170Reversal of keratinized lesions in vitamin A deficient hamster tracheal organ culture assessed as cultures with keratin and keratohyaline granules at 10 nM after 7 days (Rvb = 93%)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID442507Antioxidant activity assessed as inhibition of AAPH-induced lipid peroxidation at 100 uM2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Syntheses and evaluation of the antioxidant activity of acitretin analogs with amide bond(s) in the polyene spacer.
AID442509Inhibition of soybean lipoxygenase assessed as conversion of sodium linoleate to 13-hydroperoxylinoleate at 100 uM2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Syntheses and evaluation of the antioxidant activity of acitretin analogs with amide bond(s) in the polyene spacer.
AID567885Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 72 hrs by WST-1 assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Syntheses, antiproliferative activity and theoretical characterization of acitretin-type retinoids with changes in the lipophilic part.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID548958Inhibition of soybean lipoxygenase at 0.05 mM2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID420836Inhibition of Dictyostelium discoideum AX2 RNase P by double reciprocal plot2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Preparation of spermine conjugates with acidic retinoids with potent ribonuclease P inhibitory activity.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID442506Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins by spectrophotometry2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Syntheses and evaluation of the antioxidant activity of acitretin analogs with amide bond(s) in the polyene spacer.
AID1130654Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas compound treated ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,187)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990101 (8.51)18.7374
1990's200 (16.85)18.2507
2000's304 (25.61)29.6817
2010's413 (34.79)24.3611
2020's169 (14.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.81 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index160.55 (26.88)
Search Engine Supply Index2.41 (0.95)

This Compound (79.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials95 (7.15%)5.53%
Reviews0 (0.00%)6.00%
Reviews191 (14.38%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies582 (43.83%)4.05%
Observational0 (0.00%)0.25%
Observational8 (0.60%)0.25%
Other7 (100.00%)84.16%
Other452 (34.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin [NCT05203354]Phase 460 participants (Actual)Interventional2018-09-01Completed
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation [NCT02330380]26 participants (Actual)Observational2013-04-30Completed
Retinoic Acid Effect on Cell Surface Molecules in Vivo [NCT03753867]Phase 10 participants (Actual)Interventional2019-01-07Withdrawn(stopped due to The study was withdrawn.)
Pilot Study of Acitretin for Treatment of Erlotinib-induced Skin Rash [NCT01299220]Phase 40 participants (Actual)Interventional2010-11-30Withdrawn(stopped due to Unable to enroll subjects by sponsor deadline)
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis Compared to Standard Care --- a Pragmatic Observational Study [NCT04537689]Phase 440 participants (Anticipated)Interventional2020-12-10Recruiting
EFFICACY AND SAFETY OF ACITRETIN IN DOSES OF 25mg,35mg or50mg IN PATIENTS WITH SEVERE PLAQUE TYPE PSORIASIS: A RANDOMISED,DOUBLE BLIND , PARALLEL GROUP DOSE- RANGING STUDY [NCT01039142]Phase 461 participants (Actual)Interventional2008-03-31Completed
Multi-center, Randomized, Double Blind, Placebo Parallel-Controlled Study of the Efficacy and Safety of Total Glucosides of Paeony Combined With Acitretin Capsules to Treat Psoriasis Vulgaris [NCT02191020]108 participants (Actual)Interventional2013-02-28Completed
Evaluation of the Effect of Acitretin Versus Narrowband Ultraviolet B on Serum Neopterin Level in Psoriatic Patients . [NCT05401006]Phase 430 participants (Anticipated)Interventional2021-06-05Active, not recruiting
Enumeration and Functional Evaluation of Regulatory T-cells in Psoriasis Patients Before and After Treatment With: Calcipotriol/Betamethasone, Acitretin, Narrow-Band UVB and Anti-TNF Alpha Therapy (Etanercept, Adalimumab and Infliximab) [NCT01233583]38 participants (Actual)Observational2010-06-30Completed
An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17. [NCT01228409]Phase 420 participants (Anticipated)Interventional2010-10-31Recruiting
Changes of Cerebral Spinal Fluid APPSα Levels Under Oral Therapy With Acitretin 30 mg Daily in Patients With Mild to Moderate Alzheimer's Disease: a Multicenter Prospective Randomised Placebo-controlled Parallel-group Study [NCT01078168]Phase 222 participants (Actual)Interventional2010-03-31Completed
Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis Compared to Standard Care --- a Pragmatic Observational Study [NCT04239859]Phase 440 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin [NCT00723437]Phase 436 participants (Actual)Interventional2005-01-31Completed
A Multicenter, Randomized, Open Pilot Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly Followed Etanercept 25mg Twice Weekly, the Combination of Etanercept 25 mg Twice Weekly and Acitretin and Acitretin Alone in Patients With Moder [NCT00936065]Phase 460 participants (Actual)Interventional2009-07-31Completed
Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules [NCT02715960]Phase 2500 participants (Anticipated)Interventional2015-12-31Recruiting
Acitretin Plasma Levels Under Hemodialysis [NCT00488384]Phase 40 participants (Actual)Interventional2007-06-30Withdrawn(stopped due to lack of subjects)
Chemoprevention Trial of Acitretin Versus Placebo in Patients at High Risk for Basal Cell Carcinoma or Squamous Cell Carcinoma [NCT00644384]130 participants (Anticipated)Interventional2003-02-28Completed
Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis [NCT00707070]Phase 4100 participants (Anticipated)Interventional2008-09-30Not yet recruiting
Plexin B2 Gene Expression and Polymorphisms in Psoriasis : Relation to NB-UVB, Acitretin and Combined Therapy [NCT05184348]Phase 1200 participants (Actual)Interventional2021-09-01Completed
Randomized, Controlled Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis [NCT00832364]Phase 40 participants (Actual)Interventional2009-10-31Withdrawn(stopped due to Business decision. No patients were enrolled)
Assessment of the Combined Effect of Acitretin and Narrow Band Ultraviolet B (Nb-UVB) on the Clinical Repigmentation and on the Expression of E-cadherins in Vitiligo Lesions in Comparison to Narrow Band UVB Alone. A Pilot Study [NCT04245319]20 participants (Anticipated)Interventional2020-01-01Recruiting
Pilot, Single-Arm Study of the Effect of Adding Acitretin to Etanercept Therapy in Patients With Moderate to Severe Psoriasis Who Fail to Respond to Etanercept Monotherapy [NCT00156247]Phase 210 participants (Actual)Interventional2005-09-30Completed
Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis [NCT01545284]Phase 2/Phase 39 participants (Actual)Interventional2012-03-31Completed
[NCT00395941]Phase 240 participants (Actual)Interventional2006-12-31Completed
[NCT01812954]1 participants (Actual)Observational2013-03-31Completed
A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris [NCT01443338]Phase 4720 participants (Anticipated)Interventional2011-09-30Recruiting
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients [NCT00002143]Phase 330 participants InterventionalCompleted
Addition of 308-nm Excimer Laser to Acitretin Therapy in the Management of Palmoplantar Psoriasis [NCT02181790]Phase 42 participants (Actual)Interventional2014-06-30Terminated(stopped due to Lack of subjects)
A Comparison of Treatment of Psoriasis With Acitretin or Tazarotene Gel 0.1% and Active or Sham Treatments With the 308 nm Excimer Laser [NCT01094717]13 participants (Actual)Interventional2010-01-31Terminated(stopped due to lack of efficacy and lack of funding)
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers [NCT00003611]129 participants (Actual)Interventional2000-05-31Completed
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma [NCT02050321]Phase 22 participants (Actual)Interventional2013-12-31Terminated(stopped due to Pharmaceutical company pulled support for the trial.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00156247 (3) [back to overview]Percent of Patients Achieving PASI 75 at 6 Months After the Addition of Acitretin Therapy
NCT00156247 (3) [back to overview]Percent of Patients Achieving a PGA of Clear or Almost Clear at 6 Months After the Addition of Acitretin Therapy
NCT00156247 (3) [back to overview]Percent of Patients Achieving PASI 50 at 6 Months After the Addition of Acitretin Therapy
NCT00936065 (33) [back to overview]Time to Achieve a PASI 75 Score
NCT00936065 (33) [back to overview]Time to Achieve a Status on the PGA of Psoriasis of Clear or Almost Clear
NCT00936065 (33) [back to overview]Time to Achieve a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild
NCT00936065 (33) [back to overview]"Change From Baseline in the Percentage of Participants Who Responded Yes to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24"
NCT00936065 (33) [back to overview]"Change From Baseline in the Percentage of Participants Who Responded Yes to the Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 17, at Weeks 2, 4, 8, 12, 18 and 24"
NCT00936065 (33) [back to overview]Change From Baseline in Percent Body Surface Area (BSA) Involvement of Psoriasis at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 1, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 10, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 11, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 12, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 13, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 14, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 15, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 16, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 2, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 5, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 4, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 6, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 7, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 8, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 9, at Weeks 2, 4, 8, 12, 18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in SGA of Itching at Each Visit
NCT00936065 (33) [back to overview]Change From Baseline in SGA of Psoriasis at Weeks 2, 4, 8, 12 ,18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in Subject Global Assessment (SGA) of Joint Pain at Weeks 2, 4, 8, 12 ,18 and 24
NCT00936065 (33) [back to overview]Change From Baseline in the PASI Score
NCT00936065 (33) [back to overview]Change From Baseline in the PGA of Psoriasis
NCT00936065 (33) [back to overview]Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score
NCT00936065 (33) [back to overview]Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear
NCT00936065 (33) [back to overview]Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild
NCT00936065 (33) [back to overview]Percentage of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear
NCT00936065 (33) [back to overview]Percentage of Participants Achieving a 75 Percent (%) Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 24
NCT00936065 (33) [back to overview]Time to Achieve a PASI 50 Score
NCT00936065 (33) [back to overview]Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 3, at Weeks 2, 4, 8, 12, 18 and 24
NCT01078168 (1) [back to overview]Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline
NCT01094717 (3) [back to overview]Change in the NPF Psoriasis Score of Plaques
NCT01094717 (3) [back to overview]Number of Patients That Achieved an Average Lesion Assessment Score of 0 or 1 at Week 12.
NCT01094717 (3) [back to overview]Number of Participants With Adverse Events
NCT02050321 (1) [back to overview]Number of Participants With Adverse Events

Percent of Patients Achieving PASI 75 at 6 Months After the Addition of Acitretin Therapy

Percentage of participants achieving at least a 75% decrease (improvement) from Baseline in the Psoriasis Area and Severity Index (PASI) at 6 months. PASI Score incorporates measures of erythema, desquamation, infiltration, and affected body surface area. Involvement and severity of psoriasis was scored using a scale of 0 to 72, where 0 = no psoriasis and 72 = severe disease. (NCT00156247)
Timeframe: 6 months

Interventionpercent (Number)
Etanercept With Acitretin12.5

[back to top]

Percent of Patients Achieving a PGA of Clear or Almost Clear at 6 Months After the Addition of Acitretin Therapy

Percentage of participants achieving a clear (0) or almost clear (1) status on the Physician Global Assessment (PGA) at 6 months. This index evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The assessment was scored on a scale of 0 to 5, where 0 = clear, with no evidence of plaque elevation, erythema, or scale, and 5 = severe induration, erythema, and scaling. (NCT00156247)
Timeframe: 6 months

Interventionpercent (Number)
Etanercept With Acitretin37.5

[back to top]

Percent of Patients Achieving PASI 50 at 6 Months After the Addition of Acitretin Therapy

Percentage of participants achieving at least a 50% decrease (improvement) from Baseline in the Psoriasis Area and Severity Index (PASI) at 6 months. PASI Score incorporates measures of erythema, desquamation, infiltration, and affected body surface area. Involvement and severity of psoriasis was scored using a scale of 0 to 72, where 0 = no psoriasis and 72 = severe disease. (NCT00156247)
Timeframe: 6 months

Interventionpercent (Number)
Etanercept With Acitretin50

[back to top]

Time to Achieve a PASI 75 Score

PASI 75 defined as a 75% or greater improvement in PASI score from Baseline (NCT00936065)
Timeframe: Baseline up to Week 24

Interventiondays (Median)
Etanercept126
Etanercept and Acitretin146
AcitretinNA

[back to top]

Time to Achieve a Status on the PGA of Psoriasis of Clear or Almost Clear

PGA of Psoriasis: score based on dermatologist's assessment of disease averaged over all lesions of head, scalp, and neck. Overall lesions were graded for induration, erythema, and scaling; range: 0 (no evidence) to 5 (severe). The sum of the 3 scores was divided by 3 to obtain a final PGA score. Higher scores indicate greater severity of disease. Assessment of clear or almost clear = PGA score of 0 (no evidence), or 1 (minimal/faint). (NCT00936065)
Timeframe: Baseline up to Week 24

Interventiondays (Median)
Etanercept167
Etanercept and Acitretin165
AcitretinNA

[back to top]

Time to Achieve a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild

PGA of Psoriasis: score based on dermatologist's assessment of disease averaged over all lesions of head, scalp, and neck. Overall lesions were graded for induration, erythema, and scaling; range: 0 (no evidence) to 5 (severe). The sum of the 3 scores was divided by 3 to obtain a final PGA score. Higher scores indicate greater severity of disease. Assessment of clear or almost clear or mild = PGA score of 0 (no evidence), 1 (minimal/faint), or 2 (mild). (NCT00936065)
Timeframe: Baseline up to Week 24

Interventiondays (Median)
Etanercept57
Etanercept and Acitretin57
Acitretin169

[back to top]

"Change From Baseline in the Percentage of Participants Who Responded Yes to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24"

"Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to answer the following question with either a yes or no, Taking into account your psoriasis symptoms, the appearance of your skin, medicine side effects and medicine ease/difficulty of use, do you consider that your current psoriasis treatment is satisfactory? Percentage of participants who responded yes reported." (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
Interventionpercentage of participants (Number)
BaselineWeek 2Week 4Week 8Week 12Week 18Week 24
Acitretin33.3350.0055.5666.6761.1161.1155.56
Etanercept38.1080.9585.7190.4895.2490.4880.95
Etanercept and Acitretin42.1178.9594.7489.4773.6894.7494.74

[back to top]

"Change From Baseline in the Percentage of Participants Who Responded Yes to the Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 17, at Weeks 2, 4, 8, 12, 18 and 24"

"Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to answer the following question with either a yes or no, Taking into account your psoriasis symptoms, the appearance of your skin and all other problems which psoriasis causes, do you consider that your current health state is satisfactory? Percentage of participants who responded yes reported." (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionPercentage of participants (Number)
BaselineWeek 2Week 4Week 8Week 12Week 18Week 24
Acitretin22.2227.7833.3333.3333.3338.8938.89
Etanercept9.5214.2942.8657.1471.4371.4357.14
Etanercept and Acitretin15.7942.1152.6357.8957.8963.1673.68

[back to top]

Change From Baseline in Percent Body Surface Area (BSA) Involvement of Psoriasis at Weeks 2, 4, 8, 12, 18 and 24

Change from Baseline in the percentage of the surface area of the body affected by psoriasis. Change = Week x minus Baseline, where smaller scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
Interventionpercentage of BSA (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin39.75-0.36-0.75-5.14-5.08-9.25-10.30
Etanercept32.98-2.64-7.36-12.67-15.43-16.57-17.52
Etanercept and Acitretin32.50-1.55-4.50-7.97-10.29-14.76-16.87

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 1, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the overall appearance of their skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin0.440.280.500.780.561.061.11
Etanercept0.670.811.572.102.102.241.76
Etanercept and Acitretin0.740.790.951.581.741.952.05

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 10, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on their anxiety. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin2.22-0.39-0.610.330.220.560.67
Etanercept2.291.051.241.571.521.571.24
Etanercept and Acitretin1.890.631.211.471.681.531.58

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 11, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on their depression. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin2.33-0.11-0.220.280.170.610.67
Etanercept2.430.951.331.381.711.571.19
Etanercept and Acitretin1.951.111.261.471.581.471.68

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 12, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on their fatigue. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin2.78-0.72-0.56-0.33-0.89-0.61-0.67
Etanercept2.950.480.290.290.480.480.24
Etanercept and Acitretin1.740.890.680.950.951.371.21

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 13, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on how others responded to their personal appearance at work/school. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin1.83-0.39-0.33-0.22-0.330.11-0.11
Etanercept2.290.001.051.000.950.950.95
Etanercept and Acitretin1.530.530.741.111.531.421.63

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 14, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on how their skin affected social and leisure activities. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin1.39-0.060.220.28-0.060.500.28
Etanercept0.950.571.101.762.101.901.57
Etanercept and Acitretin0.890.740.891.581.891.681.95

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 15, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with their psoriasis therapy in general. Responses were based on a 5-point scale: very dissatisfied (0), dissatisfied (1), neither satisfied nor dissatisfied (2), satisfied (3), very satisfied (4). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin1.410.180.120.530.350.820.76
Etanercept1.191.241.671.671.901.861.38
Etanercept and Acitretin1.371.001.001.371.531.741.68

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 16, at Weeks 2, 4, 8, 12, 18 and 24

"Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to respond to the statement I would like to continue with my current psoriasis treatment. Responses were based on a 5-point scale: strongly disagree (0), disagree(1), neither agree nor disagree (2), agree (3), strongly agree (4). Change = Week X minus Baseline, where larger scores indicate improvement." (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin2.820.00-0.120.06-0.29-0.29-0.18
Etanercept3.100.480.670.520.480.480.14
Etanercept and Acitretin3.420.110.050.260.160.210.11

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 2, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on the flaking of their skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin0.560.390.941.110.831.281.17
Etanercept1.001.141.572.382.672.331.90
Etanercept and Acitretin0.841.210.681.531.631.892.21

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 5, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on bleeding of the skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin2.890.280.560.440.780.670.61
Etanercept2.810.571.001.431.431.381.00
Etanercept and Acitretin2.840.680.741.050.741.160.84

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 4, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on tightness in the skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin1.83-0.110.440.830.610.780.56
Etanercept1.331.482.192.432.672.481.90
Etanercept and Acitretin1.110.420.791.321.742.052.00

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 6, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on burning sensation of the skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin2.28-0.44-0.060.780.560.610.44
Etanercept2.810.570.760.861.141.240.67
Etanercept and Acitretin2.370.370.891.371.161.581.05

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 7, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on skin pain. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin2.720.280.500.890.781.000.67
Etanercept2.950.480.901.241.291.100.62
Etanercept and Acitretin2.210.891.001.321.321.631.37

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 8, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on joint pain. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin4.170.170.220.330.00-0.280.17
Etanercept4.43-0.33-0.52-0.33-0.29-0.14-0.57
Etanercept and Acitretin3.79-0.050.050.210.210.370.05

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 9, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on their comfort level with their personal appearance. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin0.83-0.11-0.110.440.170.720.78
Etanercept1.140.430.901.481.521.901.57
Etanercept and Acitretin0.790.631.051.581.891.682.21

[back to top]

Change From Baseline in SGA of Itching at Each Visit

Participants were asked to rate the severity of their psoriasis itching on a 6-point scale, where 0=good and 5=severe. Change = Week X minus Baseline, where smaller scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12 ,18 and 24

,,
Interventionunits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin3.72-0.39-0.39-1.28-1.22-1.17-1.06
Etanercept3.33-0.67-1.52-1.86-2.10-1.81-1.19
Etanercept and Acitretin3.110.28-0.61-1.06-1.44-1.83-1.83

[back to top]

Change From Baseline in SGA of Psoriasis at Weeks 2, 4, 8, 12 ,18 and 24

Participants were asked to rate the severity of their psoriasis disease activity on a 6-point scale, where 0=good and 5=severe. Change = Week X minus Baseline, where smaller scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12 ,18 and 24

,,
Interventionunits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin4.72-0.72-0.83-1.67-1.61-1.83-1.72
Etanercept3.90-0.90-1.86-2.29-2.67-2.57-1.81
Etanercept and Acitretin3.94-0.33-0.94-1.89-2.28-2.11-2.39

[back to top]

Change From Baseline in Subject Global Assessment (SGA) of Joint Pain at Weeks 2, 4, 8, 12 ,18 and 24

Participants were asked to rate the severity of their joint pain on a 6-point scale, where 0=good and 5=severe. Change = Week X minus Baseline, where smaller scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
Interventionunits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin0.94-0.44-0.72-0.56-0.44-0.44-0.61
Etanercept0.670.000.290.190.00-0.050.29
Etanercept and Acitretin0.560.00-0.06-0.22-0.28-0.28-0.39

[back to top]

Change From Baseline in the PASI Score

Combined assessment of lesion severity, area affected into single score; range:0(no disease) to 72(maximal disease).Body divided into 4 sections (head, arms, trunk, legs); each area scored by itself and scores combined for final PASI. For each section, area of skin involved was estimated:0(0%) to 6(90-100%), severity estimated by clinical signs: erythema, induration, desquamation; scale: 0(none) to 4(maximum). Final PASI = sum of severity parameters for each section * area score * weight of section(head:0.1,arm:0.2,body: 0.3, leg:0.4). Change=Week X-Baseline, smaller scores show improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
Interventionunits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin26.31-3.17-4.06-6.84-6.71-8.77-9.62
Etanercept20.83-5.38-9.98-11.11-11.97-12.13-12.16
Etanercept and Acitretin19.75-3.27-6.45-9.96-11.39-13.54-13.92

[back to top]

Change From Baseline in the PGA of Psoriasis

PGA of Psoriasis: score based on dermatologist's assessment of disease averaged over all lesions of head, scalp, and neck. Overall lesions were graded for induration, erythema, and scaling; range: 0 (no evidence) to 5 (severe). The sum of the 3 scores was divided by 3 to obtain a final PGA score. Higher scores indicate greater severity of disease. Assessment of clear = PGA score of 0 (no evidence). Change = Week x, minus Baseline, where smaller scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18, and 24

,,
Interventionunits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin3.500.02-0.26-0.43-0.48-0.69-0.71
Etanercept3.40-0.51-1.00-1.34-1.62-1.58-1.67
Etanercept and Acitretin3.38-0.35-0.84-1.09-1.42-1.68-1.86

[back to top]

Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score

Combined assessment of lesion severity and area affected into single score; range: 0 (no disease) to 72 (maximal disease). Body was divided into 4 sections (head, arms, trunk, legs); each area scored by itself and scores combined for final PASI. For each section, area of skin involved was estimated: 0 (0%) to 6 (90 - 100%), and severity estimated by clinical signs: erythema, induration, and desquamation; scale: 0 (none) to 4 (exceptionally striking). Final PASI = sum of severity parameters for each section * area score * weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). (NCT00936065)
Timeframe: Weeks 2, 4, 8, 12, 18, and 24

,,
Interventionpercentage of participants (Number)
Week 2Week 4Week 8Week 12Week 18Week 24
Acitretin011.1127.7822.2238.8944.44
Etanercept4.7647.6271.4376.1976.1971.43
Etanercept and Acitretin015.7957.8978.9584.2184.21

[back to top]

Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear

PGA of Psoriasis: score based on dermatologist's assessment of disease averaged over all lesions of head, scalp, and neck. Overall lesions were graded for induration, erythema, and scaling; range: 0 (no evidence) to 5 (severe). The sum of the 3 scores was divided by 3 to obtain a final PGA score. Higher scores indicate greater severity of disease. Assessment of clear or almost clear = PGA score of 0 (no evidence), or 1 (minimal/faint). (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
Interventionpercentage of participants (Number)
BaselineWeek 2Week 4Week 8Week 12Week 18Week 24
Acitretin05.5611.115.565.5616.6716.67
Etanercept0019.0528.5742.8633.3352.38
Etanercept and Acitretin005.2621.0521.0531.5852.63

[back to top]

Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild

PGA of Psoriasis: score based on dermatologist's assessment of disease averaged over all lesions of head, scalp, and neck. Overall lesions were graded for induration, erythema, and scaling; range: 0 (no evidence) to 5 (severe). The sum of the 3 scores was divided by 3 to obtain a final PGA score. Higher scores indicate greater severity of disease. Assessment of clear or almost clear or mild = PGA score of 0 (no evidence), 1 (minimal/faint), 2 (mild). (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
Interventionpercentage of participants (Number)
BaselineWeek 2Week 4Week 8Week 12Week 18Week 24
Acitretin16.6711.1116.6727.7833.3338.8933.33
Etanercept14.2933.3342.8661.9076.1980.9576.19
Etanercept and Acitretin5.2626.3247.3742.1178.9584.2184.21

[back to top]

Percentage of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear

PGA of Psoriasis: score based on dermatologist's assessment of disease averaged over all lesions of head, scalp, and neck. Overall lesions were graded for induration, erythema, and scaling; range: 0 (no evidence) to 5 (severe). The sum of the 3 scores was divided by 3 to obtain a final PGA score. Higher scores indicate greater severity of disease. Assessment of clear = PGA score of 0 (no evidence). (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionPercentage of participants (Number)
BaselineWeek 2Week 4Week 8Week 12Week 18Week 24
Acitretin000005.565.56
Etanercept0004.769.529.529.52
Etanercept and Acitretin000005.2610.53

[back to top]

Percentage of Participants Achieving a 75 Percent (%) Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 24

Combined assessment of lesion severity and area affected into single score; range: 0 (no disease) to 72 (maximal disease). Body was divided into 4 sections (head, arms, trunk, legs); each area scored by itself and scores combined for final PASI. For each section, area of skin involved was estimated: 0 (0%) to 6 (90 - 100%), and severity estimated by clinical signs: erythema, induration, and desquamation; scale: 0 (none) to 4 (exceptionally striking). Final PASI = sum of severity parameters for each section * area score * weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). (NCT00936065)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Etanercept52.38
Etanercept and Acitretin57.89
Acitretin22.22

[back to top]

Time to Achieve a PASI 50 Score

PASI 50 defined as a 50% or greater improvement in PASI score from Baseline (NCT00936065)
Timeframe: Baseline up to Week 24

Interventiondays (Median)
Etanercept56
Etanercept and Acitretin56
Acitretin126

[back to top]

Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 3, at Weeks 2, 4, 8, 12, 18 and 24

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on the redness of their skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement. (NCT00936065)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

,,
InterventionUnits on a scale (Mean)
BaselineChange at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 18Change at Week 24
Acitretin0.720.170.440.830.611.221.00
Etanercept0.900.860.952.052.192.052.00
Etanercept and Acitretin0.631.321.161.581.682.162.21

[back to top]

Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline

Values were assessed via Western blotting technique. Normalization was conducted using hSA levels of the individual samples. (NCT01078168)
Timeframe: baseline and 4 weeks (visit 3)

Interventionfold change (Visit 3/background) (Mean)
Acitretin1.251
Placebo0.8741

[back to top]

Change in the NPF Psoriasis Score of Plaques

mean % change in the National Psoriasis Foundation (NPF) psoriasis score of the target plaques [higher percent change in NPF score is consistent with improvement, while higher absolute NPF score is consistent with worse disease, minimum score of 0 (no disease) and maximum score of 30 (worst disease)] (NCT01094717)
Timeframe: week 8

Interventionpercentage change (Mean)
Acitretin and Excimer-64.0
Acitretin and Sham (Placebo) Excimer-52.1
Tazarotene Gel and Excimer Laser-32.7
Tazarotene Gel and Sham (Placebo) Excimer-26.9

[back to top]

Number of Patients That Achieved an Average Lesion Assessment Score of 0 or 1 at Week 12.

number of patients who achieved average lesion assessment score of 0 or 1 by the Target Plaque Sum Score (TPSS) for each arm/intervention. For the TPSS, the target plaque was assessed separately for induration, scaling, and erythema using a 6-point severity scale (0 = none and 5 = severe) and the scores were summed to produce the Target Plaque Sum Score [15-point scale; maximum (most severe) score 15]. (NCT01094717)
Timeframe: 8 weeks

Interventionparticipants (Number)
Acitretin and Excimer1
Acitretin and Sham Excimer Laser0
Tazarotene and Excimer0
Tazarotene and Sham Excimer Laser0

[back to top]

Number of Participants With Adverse Events

We will collect number and types of adverse events for the excimer-treated vs. sham-treated sites (NCT01094717)
Timeframe: 12 weeks

,,,
InterventionParticipants (Count of Participants)
any adverse eventsevere adverse events
Acitretin and Active Excimer Laser20
Acitretin and Sham Excimer Laser20
Tazarotene and Active Excimer Laser40
Tazarotene and Sham Excimer Laser40

[back to top]

Number of Participants With Adverse Events

The study period during which all AEs must be reported begins after informed consent is obtained and initiation of study treatment and ends 30 days following the last administration of study treatment or study discontinuation/termination, whichever is earlier. All adverse events will be classified using either the MedDRA term or NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (NCT02050321)
Timeframe: Baseline through 30 Days post Treatment

InterventionParticipants (Count of Participants)
Acitretin and Vemurafenib1

[back to top]